Oral renin inhibitors

TL;DR: In the chronic in vivo murine model, RAS antagonists partially attenuated the development of BVZ- or SNT-mediated cardiac dysfunction, and future clinical studies are warranted to investigate the cardioprotective effects of prophylactic treatment with RAS inhibitors.

TL;DR: Aliskiren should be considered as an alternative agent for mild-to-moderate hypertension, or as an adjunctive therapy when preferred agents fail to maintain optimal blood pressure control, and for patients who have contraindications or intolerability to other antihypertensive agents.

TL;DR: The extraction and isolation of renin and PAF-AH inhibitory peptides from the macroalgae Palmaria palmata was carried out and the effectiveness of the isolated renin inhibitory tridecapeptide IRLIIVLMPILMA was explored.

TL;DR: The renin response to aliskiren therapy may paradoxically increase blood pressure in patients with a highly reactive renin concentration, and the possible action of the increased renin concentrations on the putative renin receptor was expressed.

TL;DR: In vivo recent evidence suggest that the activation of mitogen-activated protein kinases and activator protein-1 by Ang II may play the key role in cardiovascular and renal diseases, however, there are still unresolved questions and controversies on the mechanism of Ang II-mediated cardiovascular and kidneys diseases.

TL;DR: The benefits of ACE inhibitors or ARBs on renal outcomes in placebo-controlled trials probably result from a blood-pressure-lowering effect, and in patients with diabetes, additional renoprotective actions of these substances beyond lowering blood pressure remain unproven.

TL;DR: Although the differences between patients in remission and healthy controls did not reach statistical significance, there were substantial rises in bradykinin during acute attacks of hereditary, acquired, or captopril-induced angio-oedema.

TL;DR: Once-daily oral treatment with aliskiren lowers blood pressure effectively, with a safety and tolerability profile comparable to that of irbesartan and placebo, in patients with mild-to-moderate hypertension.